1Koch Institute for Integrative Cancer Research, Massachusetts Institute for Technology, Cambridge, Massachusetts. 2Department of Biological Engineering, Massachusetts Institute for Technology, ...

The addition of the HER2 tyrosine kinase inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly increased progression-free survival (PFS) compared to a ...

Main Finding: A phase I/II trial supported the safety and efficacy of intermittent administration of VT3989 for the treatment of mesothelioma. Concept: Blocking TEAD autopalmitoylation effectively ...